News
News

mymeleon Ltd. presenting at the 13th International Food Data Conference, Lisbon

Oct 16, 2019

Zug, Switzerland, October 16, 2019 – mymeleon’s Chief Operating Officer, Dr. Paolo Colombani, and co-founder Francesco Cavalli will jointly present their work on next generation food composition databases, which incorporate biomarker-derived data, at the upcoming 13th International Food Data Conference in Lisbon, Portugal, from October 14-18 2019. The theme of the biennial Conference is «Challenges for Food Databases in the Bioinformatics Era».

mymeleon’s contribution at the conference, which includes an oral presentation, will depict a new view on the generation and use of food composition databases. The integration of food data based on the direct association of nutrients and foods with the inflammatory state of the body, represents an expansion of the classical use of food composition databases, which usually relies only on the chemical composition of the foods analysed ex-vivo and not on the effects they exert in the body. By adding values to foods that also represent direct, in-vivo metabolic effects, the potential of food composition databases will be greatly improved.

The addition of data representing the inflammatory potential of foods will form the basis for the development of foods with anti-inflammatory properties. It will also simplify the process of enacting regulations on Health Claims related to the inflammatory potential of foods. Such Health Claims will ensure that customers will be informed in an evidence-based, transparent way and protected from fraud and misleading claims. 

mymeleon will also participate in one-to-one meetings with companies, regulators, and scientists to discuss the challenges that need to be overcome by the next generation food composition databases in order to be used by all the different players and stakeholders in the field of food composition. In particular, mymeleon will present the case for the use of the inflammatory potential of foods and the other anti-inflammaging services and products of mymeleon’s ecosystem of solutions, in order to prevent chronic diseases and premature aging.

About International Food Data Conference IFDC

The IFDC is co-organized by INFOODS of the Food and Agriculture Organization (FAO) of the United Nations and this year’s local host, the Portuguese National Health Institute Instituto Nacional de Saúde Dr. Ricardo Jorge. The IFDC is the major conference on food composition databases and covers all topics from the production of analytical data to its application and interaction with users. It serves as a platform to discuss ongoing and future challenges with the generation and use of food data, which form the basis for many applications ranging from food policies and legislation to medical epidemiology, and aim at achieving better nutrition worldwide.

 

About mymeleon Ltd.

mymeleon Ltd. is a privately held, science based Swiss technology company. It endeavors to improve people’s health with its anti-inflammaging products and services. Built on a solid foundation by merging state-of-the-art science and AI, it continues the innovative philosophy of the founders who are devoted to keeping communities healthy.

 

Contact

For further information on mymeleon Ltd., please contact info@mymeleon.com;
www.mymeleon.com

For further information on mymeleon’s participation at the IFDC, please contact Dr. P. Colombani directly: paolo.colombani@mymeleon.com

 

Download file: EN

Posted by mymeleonnewsta
News
News

mymeleon Ltd. appoints Dr. Paolo Colombani as Chief Operating Officer

Oct 15, 2019

Zug, Switzerland, October 1, 2019 — mymeleon Ltd. is pleased to announce the appointment of Dr. Paolo Colombani as Chief Operating Officer and member of the executive with effect from October 1, 2019. Paolo brings more than 25 years’ experience of working internationally as a scientist, most of it at one of the leading Universities of the World, the ETH Zurich. He always focused on a holistic view to integrate the relevant factors responsible for performance and maintaining human health and to bridge the gap between science and the general population. 

Dr. Christoph von Arb, President of the board said: “I am very pleased and honoured that Dr. Colombani has joined the mymeleon team. He will be key to realizing the full potential of our assets and making strategic decisions on how to implement them. Paolo brings a wealth of experience and broad expertise covering substantial parts of the scientific background. He also has the necessary understanding of the IT and global environment. I look forward to working with Paolo as he creates and builds our operating organization to turn our cutting edge technologies into anti-inflammaging products and services to benefit the global community.”

Paolo Colombani commented: “I am thrilled to join the mymeleon executive team at this critical stage, where high class scientific evidence are being merged with cutting edge technologies in Artificial Intelligence in order to provide personalized healthcare to the public. The time is truly ripe as it only recently became clear that many of our non-communicable diseases like diabetes, adiposity, or depression share the common ground of a low-grade chronic inflammation and, thus, the preventive measures can be focused on reducing this particular type of inflammation, which is also associated with premature aging. The anti-inflammaging approach of mymeleon via API has an enormous potential for all of us. Through the collaboration with large companies with many clients and users we will empower many people to live a longer and healthier life with less disabilities.”

 

About Dr. Paolo Colombani

Paolo Colombani studied Food Engineering, and earned his PhD, at ETH Zurich. For the first 15 years of his career, Paolo worked at ETH Zurich as a lecturer and researcher, at the intersection of food, nutrition, and physical activity in relation to metabolic responses, health maintenance and disease prevention. Paolo played an integral role in directing the Swiss food composition database towards international standardization and consequently, became president of EuroFIR, the European not-for-profit association for food composition databases, which originated from a Network of Excellence of the European Commission. Paolo’s scientific services and technical expertise have been engaged by the Swiss Government, Swiss Olympic, Antidoping Switzerland, the food industry, several national and professional sporting teams including FC Basel, individual elite athletes, and by many Swiss medical and health associations, to which he regularly offers further education programs in nutrition, physiology and metabolic health. Paolo has amassed a vast scientific experience and developed his leadership over the course of his career, through his participation in large-scale research projects of the European Commission; organizing and leading many scientific projects and several transnational conferences; supervising more than hundred student theses; acting as an executive board member of several professional associations, including the Swiss Society of Nutrition; founding the Swiss Sports Nutrition Society and becoming its first president; and most recently, being appointed CSO of a start-up in the field of weight management as well as developing a new line of premium food supplements. Paolo is also co-founder of mymeleon and involved in its activities since 2015.

 

About mymeleon Ltd.

mymeleon Ltd. is a privately held, science based Swiss technology company. It endeavors to improve people’s health with its anti-inflammaging products and services. Built on a solid foundation by merging state-of-the-art science and AI, it continues the innovative philosophy of the founders who are devoted to keeping communities healthy.

 

Contact

For further information on mymeleon Ltd., please contact info@mymeleon.com;
www.mymeleon.com

 

Download file: EN

Posted by mymeleonnewsta
Press Release
Press Release

mymeleon Ltd. elects its chairman and vice-chairman

Oct 15, 2019

Zug, Switzerland, May 15, 2019 — mymeleon Ltd. is pleased to announce the election of Dr. Christoph von Arb as chairman of the board and Prof. Tariq Mughal as vice-chairman. The unanimous elections of Dr. von Arb and Prof. Mughal foster the vision of mymeleon to be the primary disease prevention company by leading the transition towards health protection, and to enable B2B partners to keep their community of users healthy.

Dr. von Arb’s experience in international affairs and at the interface between academia, industry and government, will nurture mymeleon’s initiative to bring evidence-based scientific know-how and solutions in the prevention of low-grade chronic inflammation to the B2B partners. Professor Mughal, representing the medical community, will ensure that the solutions provided by mymeleon are relevant and contribute in a significant manner to disease prevention and health maintenance. 

Patrick Pozzorini, CFO, commented, “I am very pleased that the board elected two of its members as chairman and vice-chairman who perfectly emphasize the vision and mission of mymeleon. Their significant experience in transferring scientific know-how and establishing fruitful partnerships among stakeholders with different backgrounds, are important assets that will ease the growth of mymeleon.”

 

About Dr. Christoph von Arb

Dr. Christoph A. von Arb is President and Founder of Swiss-based International Initiatives Inc. – TRIPLEYE, a private consulting firm with a specific focus on ERI at the interface between industry, academia and government. He gained his experience in international affairs during his diplomatic service abroad. In the late 90s, he negotiated Switzerland’s full participation in the EU-Research Framework Programs. From 2002 to 2008, Dr. von Arb was Consul-General and Director of the world’s first Digital Science Consulate – swissnex – in Boston, a novel concept of diplomacy based on public-private partnership, which he initiated and implemented. Dr. von Arb is a frequent lecturer at universities and public events and serves on several boards. He received his Ph.D. in Plant Molecular Biology in 1984 from the University of Bern.

 

About Prof Tariq Mughal

Tariq Mughal qualified in medicine at St George’s Hospital Medical School in London (UK), followed by postgraduate training in Hematology, Medical Oncology and Stem Cell Transplantation at the Imperial College London (Hammersmith Hospital) and the University of Colorado School of Medicine, Denver. He is a Professor of Haematology/Oncology at the Tufts University Cancer Center (Boston) and University of Buckingham (UK). His principal research interests are in precision cancer medicine and hematological malignancies, melanoma and breast cancer. He has published over 130 peer-reviewed papers, 33 cancer textbook chapters and authored/edited 13 cancer books. He is the recipient of a number of awards, including those from the UK Royal College of Physicians, American College of Physicians, Swiss humanitarian groups and a BMA global Book Award. Since 2012, through his foundation, Alpine Oncology Foundation, he has empowered physicians and patients to become eligible for targeted therapies for leukemias, acute and chronic, myeloid and lymphoid, in some of the poorest countries by providing educational support and assistance with diagnostic molecular tools and drug access. He serves as an editorial board member of several peer-led hematology and oncology journals and was the founding co-editor of Clinical Leukemia. He has also helped found several international and national societies.

 

About mymeleon Ltd.

mymeleon Ltd. is a privately held, science based Swiss technology company. It endeavors to improve people’s health with its anti-inflammaging products and services. Built on a solid foundation by merging state-of-the-art science and AI, it continues the innovative philosophy of the founders who are devoted to keeping communities healthy.

 

Contact

For further information on mymeleon Ltd., please contact info@mymeleon.com;
www.mymeleon.com

 

Download file: EN

Posted by mymeleonnewsta
News
News

mymeleon Ltd. – The start-up is out of the garage

Oct 15, 2019

Zug, Switzerland, May 5, 2019. Today, the mymeleon founders released a new company out of the garage. But just don’t ask for too many details yet.

On Sunday, the founders launched mymeleon, a stealth start-up using AI and cutting-edge science to give their B2B partners with large communities of users, the opportunity to empower their clients in the area of healthcare via API.

The company also announced CHF 1 million seed money, organized under the lead of Lorenzo Dell’Ovo Allori, one of the early stage investors. There were also 5 pre-seed money rounds, coordinated by the founders themselves.

The company originated from the idea of a Swiss student. Yes, a student. Francesco Cavalli is his name. One should listen to young people; they hold unbiased views. The idea was to have a simple tool which helped people to stay healthy and happy and was based on well-founded information. After numerous exchanges with the former ETH Zurich scientist Paolo Colombani and other experts, it became clear how to create the tool. It needed to be a conglomerate of human and artificial intelligence. Only with this merger one can empower a vast number of people while ensuring that everything is based on high-class, well-founded scientific evidence.

“The expert system combined with Artificial Intelligence can deliver infinite tips to fight low-grade chronic inflammation”, said Francesco, the student co-founder. “Applying that approach to healthcare”, he said, “we can also reduce the economic burden related to diseases by keeping the community happy and healthy. No doubt about that”.

While the company won’t provide any details about its products until customer testing is finished later this year, the mymeleon’s expert team will continue to expand on the already solid scientific fundamentals and create additional algorithms to increase the accuracy of the predictive AI model, upon which the Anti-Inflammaging API relies.

Vera Cavalli, Fabio Cavalli, and Patrick Pozzorini spent 10 years at mondoBIOTECH AG, a pioneer in rare and neglected diseases, rising from a start-up to an international and listed company with more than 2,4 billion market cap on the Swiss stock exchange. Now, with advancements in technology, the analysis of big data in nutrition, physical activity, cognition, and environment, and the creation of personalized tips with the help of AI, has become reality. 

The mymeleon company started in 2015 and since then the number of people involved increased steadily. Among them, in absolute random order, Marco Pozzo, former chairman of Sigma, an IT company sold to an Italian listed company; Kellie Pritchard-Peschek, PhD, sports scientist from Brisbane; Michele Libutti, an MD from the Mediterranean region; Tariq Mughal, MD, professor in haematology and oncology from Tufts University Boston.

And the name? We saw a chameleon changing colour based on its behaviour. We thought, let’s see if we can change our colour by changing our behaviour like they do. Only that our colour mirrors our state of low-grade chronic inflammation. You also think that is a nice idea? That’s exactly why we already patented it.

So, that’s mymeleon. Let’s now start keeping our communities healthy and happy.

 

About mymeleon Ltd.

mymeleon Ltd. is a privately held, science based Swiss technology company. It endeavors to improve people’s health with its anti-inflammaging products and services. Built on a solid foundation by merging state-of-the-art science and AI, it continues the innovative philosophy of the founders who are devoted to keeping communities healthy.

 

Contact

For further information on mymeleon Ltd., please contact info@mymeleon.com;
www.mymeleon.com

 

Download file: EN

Posted by mymeleonnewsta